Viewing StudyNCT05244993

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 5:14 PM
Last Modification Date: 2024-10-26 @ 2:25 PM
Study NCT ID: NCT05244993
Status: UNKNOWN
Last Update Posted: 2022-07-12
First Post: 2022-02-08
Brief Title: AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Sponsor: Liaoning Tumor Hospital Institute
Organization: Liaoning Tumor Hospital Institute
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Breast Neoplasm Female
Keywords: